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pression of TNF-  in endothelial cells increased angio-
genic sprout formation in the presence but also in the 
absence of angiogenic growth factors. The partial neu-
tralization of this effect by TNF-  antibodies and the in-
ability of conditioned media from stable TNF-  -express-
ing endothelial cells to induce angiogenic activities in 
control endothelial cells suggest that this effect does not 
require expression of additional autocrine factors, but is 
an autonomous effect of the transmembrane TNF on the 
endothelial cells. Furthermore, using the Matrigel plug 
assay in vivo, increased angiogenesis was observed in 
endothelial TNF-  -expressing transgenic versus control 
mice. In conclusion, chronic infl ammatory changes me-
diated by TNF-  can induce angiogenesis in vitro and in 
vivo, suggesting endothelial cell activation as a direct 
link between infl ammation and angiogenesis. 
 Copyright © 2006 S. Karger AG, Basel 
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 Abstract 
 There is increasing evidence that chronic infl ammation 
is tightly linked to diseases associated with endothelial 
dysfunction, including the induction of aberrant angio-
genesis. While leukocytes have been described as me-
diators of infl ammation-associated angiogenesis, the ef-
fects of direct chronic endothelial activation have not 
been addressed in this context. Using an uncleavable 
mutant of the transmembrane form of tumor necrosis 
factor-  (TNF-  ), we have established models of stable 
TNF-  expression in endothelial cells in vitro and in 
transgenic mice in vivo. In the in vitro model, continuous 
endothelial activation leads to increased leukocyte cel-
lular adhesion molecule expression and intracellular re-
active oxygen species, hallmarks of a proinfl ammatory 
and dysfunctional endothelium. In addition, stable ex-
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 Introduction 
 Endothelial cell activation is essential for many vascu-
lar pathologic processes, leading to inﬂ ammation, vascu-
lar remodeling, and vessel growth. In diseases associated 
with chronic inﬂ ammation, such as atherosclerosis, endo-
thelial activation plays a role in both initiation and pro-
longation and exacerbation of the pathology. Such chron-
ic endothelial activation is accompanied by endothelial 
dysfunction, characterized by sustained expression of 
leukocyte adhesion molecules, and thus, sustained leuko-
cyte involvement, vascular permeability, dysregulation 
of vasoreactivity, a thrombogenic propensity, abnormal 
blood vessel remodeling, and, last but not least, angiogen-
esis  [1] . Angiogenesis, the process of new blood vessel 
formation, is essential for embryonic growth, wound 
healing, the female reproductive cycle, and pregnancy in 
physiological settings  [2, 3] . In contrast, excessive angio-
genesis is noted in tumors, rheumatoid arthritis, athero-
sclerosis, psoriasis, obesity, inﬂ ammatory bowel disease, 
primary pulmonary hypertension, diabetic retinopathy, 
asthma, and advanced macular degeneration of the eye 
 [3, 4] . 
 The ﬁ nding that inﬂ ammation is often associated with 
increased angiogenesis was explained by inﬂ ammation-
induced production of angiogenic factors, either from 
vascular or other tissue cells, or from inﬁ ltrating leuko-
cytes. Proinﬂ ammatory mediators, such as tumor necro-
sis factor-  (TNF-  ), are known to activate the endothe-
lium and increase expression of adhesion molecules and 
chemokines, which are critical steps for leukocyte recruit-
ment  [1] . These recruited leukocytes can mediate angio-
genesis by release of endothelial growth factors  [5–7] . 
However, there is insufﬁ cient experimental study of the 
precise mechanisms in chronic situations and it is un-
known to what extent leukocyte-independent mecha-
nisms also contribute to the angiogenesis. For instance, 
acute endothelial cell activation by TNF-  can elicit di-
verse effects dependent upon the state of the cells and 
other factors present. An anti-angiogenic role of TNF-  
was suggested by the ability of soluble TNF-  receptor 
antibodies to increase endothelial cell proliferation  [8] . In 
contrast, stimulation of angiogenesis by TNF was ob-
served in the presence of either vascular endothelial 
growth factor (VEGF) or basic ﬁ broblast growth factor 
(bFGF)  [9] , which was suggested to be mediated by acti-
vation of urokinase-type plasminogen activator. Howev-
er, the role of TNF or other proinﬂ ammatory molecules 
in directly inﬂ uencing angiogenesis in chronic diseases is 
not known, despite the fact that TNF-  and the TNF-  
receptor superfamily are strongly implicated in a number 
of chronic diseases  [10–14] . 
 TNF-  , the founding member of the TNF family of 
cytokines, is produced as a transmembrane spanning pre-
cursor protein (tmTNF-  ) and a proteolytically cleaved 
soluble form. Given the correlation of soluble TNF-  con-
centration in plasma with infectious and inﬂ ammatory 
diseases, it is understandable that this form was soon per-
ceived as the natural form of TNF-  , while the transmem-
brane form being present or induced on a variety of im-
mune and non-immune cells (including endothelial cells) 
was widely disregarded. However, more recently, a vari-
ety of conditions that activate endothelial cells have been 
convincingly shown to express tmTNF-  in vitro and  in 
vivo  [15–22] . Despite the exponential awareness of the 
critical role for endothelial activation in many diseases, 
there is a dearth of models to study the initiating disease 
potential and direct effects of continuous endothelial ac-
tivation. In order to mimic the situation of chronic acti-
vated endothelium, we have established models of stable 
TNF-  expression in endothelial cells in vitro and in 
transgenic mice in vivo using an uncleavable mutant of 
TNF-  .  
 Using these speciﬁ c models, we demonstrated an in-
crease in cell adhesion molecules and reactive oxygen 
 species (ROS) as a measure of continuous activated en-
dothelium, a signiﬁ cant increase in sprout formation as a 
measure of in vitro angiogenesis, and increased neovas-
cularization in Matrigel plugs as a measure of in vivo an-
giogenesis. Thus, in this study, we show that angiogenesis 
could be induced per se by activated endothelium, estab-
lishing a direct link between inﬂ ammation and angio-
genesis. 
 Materials and Methods 
 Antibodies and Reagents  
 Neutralizing antibodies to TNF (clone MP6-XT3) and TNF 
receptor type I (TNFRI; clone 55R-170) were purchased from BD 
Biosciences, San Jose, Calif., and R&D Systems, Minneapolis, 
Minn., USA, respectively. Murine CD31 (Mec13.3) was from 
Pharmingen, Oxford, UK, and murine CD34 (Mec14.7) was from 
Sanbio, Beutelsbach, Germany. The hybridomas 25ZC7 (anti-in-
tercellular adhesion molecule 1; anti-ICAM-1)  [23] , 6C7 and 4B12 
(anti-vascular cell adhesion molecule 1; anti-VCAM-1)  [24] were a 
kind gift of D. Vestweber (Münster, Germany). The Matrigel was 
purchased from BD Biosciences, Heidelberg, Germany, while 
bFGF was from R&D Systems, Wiesbaden, Germany, and VEGF 165  
(heparin-binding VEGF 165  isoform also known as VEGF-A) was 
from ReliaTech, Braunschweig, Germany. 2  ,7  -dichlorodihydro-
ﬂ uorescein diacetate (H2DCFDA) and dihydroethidium (DHE) 
were from Molecular Probes, Eugene, Oreg., USA. DMEM, FCS, 
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antibiotics, apocynin, soluble TNF-  , and thrombin were from Sig-
ma Chemical Co., St. Louis, Mo., USA. Trolox was purchased from 
Calbiochem, La Jolla, Calif., USA. 
 Generation of tmTNF-  -Expressing Endothelial Cells 
 Polyoma virus middle T-transformed endothelial cells from 
wild-type newborn mice were kindly provided by F. Kiefer (Mün-
ster, Germany)  [25] and cultured in DMEM supplemented with 
10% FCS, 2 m M glutamine, and 1 ! penicillin/streptomycin. Cells 
were transfected with the uncleavable transmembrane mutant form 
of murine TNF-  [mTNF  1–9,K(11)E]  [26] by retroviral gene 
transfer. The cDNA for mTNF  1–9,K(11)E  [27] was cloned into 
the pBABE/neo vector  [28] and stably transfected into the retrovi-
rus packaging cell line GP+E86  [29] . Culture supernatants of trans-
fected GP+E86 cells supplemented with 8   g/ml polybrene were 
used for infection of endothelial cells for 3 h. Infected endothelial 
cells were selected with gentamycin-containing medium (1 mg/ml). 
Endothelial cells transfected with the empty vector were treated 
identically and used as control cells.  
 Flow Cytometric Analysis of Cell Adhesion Molecules 
 Cytoﬂ uorometric analysis (FACS) was performed as previously 
described  [18] . Both control and tmTNF-  -expressing endothelial 
cells were cultured to conﬂ uency, detached using EDTA buffer, and 
incubated with primary antibodies – hybridoma supernatant immu-
noglobulin G (IgG) in phosphate buffer supplemented with 2.5% 
FCS and 0.02% sodium azide – for 30 min at 4  °  C. After washing, 
cells were incubated with phycoerythrin-conjugated secondary anti-
body (Dianova, Hamburg, Germany) and analyzed on a FACStar 
using CellQuest software (Becton Dickinson, Heidelberg, Germany) 
drawing light scatter gates around live endothelial cell populations. 
 Real-Time Analysis of Intracellular ROS Production 
 H2DCFDA is a commonly used dye that allows the monitoring 
of intracellular ROS production in general, regardless of the precise 
enzymatic or non-enzymatic source, as it is oxidized by a number 
of oxidant species, including nitric oxide (NO)  [30] . This method 
is based on the uptake and intracellular hydrolysis of the H2DCFDA 
dye by intracellular esterases to the non-ﬂ uorescent derivative, 
DCFH, which is polar and trapped within the cells. Conﬂ uent en-
dothelial cells in 96-well black-walled plates were incubated in 
DMEM and 10   M H2DCFDA for 30 min to allow intracellular 
uptake. Cells were washed 3 times and media replaced (without dye 
but with 1% albumin). Fluorescence of the oxidized dye was sub-
sequently determined at 495 nm (excitation), 525 nm (emission), 
with 515 nm cutoff on a Flex station set for maximal detection in 
monolayer cells compared with dye alone. Non-speciﬁ c background 
ﬂ uorescence (no dye) was not different between groups (different 
cell treatments or different inhibitor additions) and was subtracted 
to give speciﬁ c relative ﬂ uorescence units. In order to verify that 
the oxidation of DCFH was dependent on ROS production, an in-
hibition dose response to the radical scavenger, Trolox, was deter-
mined with an inhibitor present throughout dye loading, washing, 
and the subsequent assay. As DCFH oxidation responds to NO as 
well  [31] , we also examined the inhibition in the presence of the 
NO synthase inhibitor, N G -nitro- L -arginine methyl esther ( L -
NAME). To assess the relative contribution of NAPDH oxidase to 
ROS formation, we analyzed the oxidation of DHE to ethidium, 
which is more speciﬁ c for superoxide, in the presence and absence 
of several concentrations of the NAPDH oxidase inhibitor, apocy-
nin. Cells were loaded 30 min with 5   M DHE, washed, and media 
replaced as for DCFH. Ethidium oxidization was determined on 
the Flex Station at 520 nm (excitation), 605 nm (emission), with 
595 nm cutoff. 
 In vitro Sprout Formation Assay 
 Angiogenesis in vitro was tested as described previously, with 
slight modiﬁ cations  [32] . Brieﬂ y, the endothelial cells were grown 
to conﬂ uence on cytodex-3 microcarrier beads (Sigma) and placed 
into a 12-well culture plate (Nalge Nunc Int., Rochester, N.Y., 
USA) containing ﬁ brinogen gel. Polymerization was started by add-
ing 0.48 U/ml thrombin. About 1 ml of the media with or without 
factors of interest was added to each well and incubated for 1 h at 
37  °  C, 5% CO 2 . After 1 h, the media was replaced with fresh media 
with the respective factors and incubation was continued. After 
24 h, the gel was ﬁ xed in 1% paraformaldehyde and the number of 
sprouts per 50 beads longer than the average bead size was counted 
under a phase contrast microscope. No signiﬁ cant morphological 
differences were noted between controls and tmTNF cell sprouts. 
Experiments were performed in triplicate and repeated at least four 
times. For inter-individual observational differences, the number 
of sprouts was also counted by a person blinded to the study de-
sign. 
 Tie2-tmTNF Transgenic Animals  
 The construction of transgene and the generation of Tie2-
tmTNF transgenic animals were described previously  [27] . These 
mice contain the cDNA of the uncleavable mTNF  1–9,K(11)E 
cloned between endothelial-speciﬁ c Tie2 promoter and the Tie2 
ﬁ rst intron in order to localize TNF-  speciﬁ c to the endothelium. 
Mice used for this study had been back-crossed for more than eight 
generations in C57BL/6 animals. Mice were used as heterozygous 
for the transgene, and non-transgenic litter mates served as wild-
type controls. 
 Angiogenesis in vivo/Matrigel Plug Assay 
 A modiﬁ ed method of the Matrigel plug assay described by Pas-
saniti et al.  [33] was used to assess angiogenesis in Tie2-tmTNF 
transgenic mice and non-transgenic littermates. Brieﬂ y, Matrigel 
was mixed with 200 ng/ml bFGF and 500 ng/ml VEGF 165 , and 
0.4 ml were subcutaneously injected into mice. After 14 days, 
Matrigel plugs were harvested, ﬁ xed in 1% paraformaldehyde for 
4.5 h on ice, and embedded in parafﬁ n. After deparafﬁ nation, al-
ternate 6-  m sections from the center of the excised Matrigel plugs 
were stained with rat monoclonal antibodies to CD31 and CD34. 
Sections were developed after incubation with a biotin-conjugated 
goat anti-rat IgG secondary antibody (Dianova, 1:  100) using the 
vectastain Elite ABC Kit (Vector Laboratories, Burlingame, Calif., 
USA) and the AEC Chromogen Kit (Sigma) according to the man-
ufacturers’ instructions. Stained cells were counted in several sec-
tions and high-power ﬁ elds (at least 20/animal), and the amounts 
of CD31- or CD34-positive cells were calculated. 
 Statistical Analysis 
 Data are expressed as mean  8 SD for each group, performed 
in triplicate for in vitro sprout assay and for the measurement of 
ROS production. Statistical signiﬁ cance was determined by ANO-
VA using the Microsoft Excel Statistical Package and by Welch’s t 
test using InStat software for the in vivo Matrigel plug assay. A 
probability value p  ! 0.05 was considered statistically signiﬁ cant. 
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 Results 
 tmTNF-  Overexpression in Endothelial Cells Leads 
to Continuous Expression of Intercellular Adhesion 
Molecules 
 We have previously reported that transfection of im-
mortalized macrovascular human umbilical cord vein en-
dothelial cells with a transmembrane uncleavable mutant 
form of TNF-  leads to continuous activation of proin-
ﬂ ammatory signal transduction pathways (p38 mitogen-
activated protein kinase and nuclear factor-  B) and tissue 
factor production  [18] . Here, we stably transfected poly-
oma middle T immortalized murine endothelial cells, 
which are of microvascular appearance, with the trans-
membrane uncleavable mutant form of TNF-  using ret-
roviral gene transfer. Expression of TNF-  in these cells 
was demonstrated by FACS analysis, whereas vector-only 
transfected control cells did not stain for TNF-  (data not 
shown). Using FACS analysis, the expression of vascular 
adhesion molecules in tmTNF-  -expressing endothelial 
cells was compared with control cells. In addition, both 
control cells and tmTNF-  stable transfected cells were 
treated with soluble TNF-  at 1 n M for 12 h. Cells stimu-
lated with soluble TNF-  (dark histogram) or untreated 
(bright histogram) were incubated with antibodies directed 
against VCAM-1 or ICAM-1 as indicated. In tmTNF-  -
expressing endothelial cells, the signals for ICAM-1 and 
VCAM-1 shift to the right indicating increased expression, 
whereas in control cells, they remain at basal levels ( ﬁ g. 1 ). 
This implies that the stable transfected tmTNF-  cells 
display constitutively increased levels of ICAM-1 and 
VCAM-1 at the surface in comparison with control cells. 
Stimulation with soluble TNF-  strongly induces VCAM-1 
and ICAM-1 surface expression in control cells, but no 
further signiﬁ cant upregulation can be seen in tmTNF-  -
expressing endothelial cell. These ﬁ ndings indicate that 
continuous endothelial cell activation leads to continuous 
and stable expression of vascular adhesion molecules, 
which mediate both acute and chronic inﬂ ammation. 
 Increased ROS Concentrations in Endothelial Cells 
Expressing tmTNF-   
 Another hallmark of activated endothelium in chron-
ic inﬂ ammation is the increased production of free ROS. 
Soluble TNF-  is known to induce the formation of ROS, 
which results from NADPH oxidase activation, but also 
induces increased expression of speciﬁ c members of the 
NADPH oxidase complex, such as the gp91 phox   [34] . 
Based on our ﬁ ndings from gene expression studies in 
tmTNF-  -expressing endothelial cells (unpublished data) 
that this subunit (NOX2 isoform) is increased 7-fold, we 
reasoned that these cells may show continuously increased 
ROS levels. When assessing intracellular ROS concentra-
tions by oxidation of DCFH (a ﬂ uorescent substrate), we 
found increased concentrations in tmTNF-  -expressing 
versus control endothelial cells, which was attenuated by 
the addition of the antioxidant Trolox ( ﬁ g. 2 a, b). As seen 
in the Trolox dose-response curve ( ﬁ g. 2 a), this inhibition 
is maximally 65%, whereas higher levels of Trolox can 
actually increase the oxidant load and increase DCFH 
oxidation. This pro-oxidant effect at a higher concentra-
tion of anti-oxidants, such as vitamin E, is well docu-
mented  [35] . Notably, addition of the NO synthase in-
hibitor,  L -NAME, further reduced DCFH oxidation 
(combined average inhibition of 97%) indicating that 
NO-mediated dye oxidation accounted for the remainder 
of the DCFH ﬂ uorescence which was not inhibited by 
Trolox alone ( ﬁ g. 2 a). Next, we assessed the potential con-
tribution of NADPH oxidase-derived superoxide to ROS 
accumulation in the tmTNF-  cells by analyzing apocy-
nin-induced inhibition of ethidium oxidation, a more 
speciﬁ c marker for superoxide generation  [36] . Similar to 
the chronic increase in ROS production in general, as de-
tected by DCFH oxidation, tmTNF-  expression signiﬁ -
cantly increased ethidium oxidation ( ﬁ g. 2 c). Apocynin 
only very modestly reduced the ethidium oxidation in 
control cells, indicating that most superoxide radicals 
were derived from other sources, such as the mitochon-
drial respiration, under basal condition in control cells. 
However, in the tmTNF-  cells, apocynin reversed 70% 
of the gain over control. This indicates that chronic acti-
vation of NADPH oxidase in the tmTNF cells impor-
tantly contributed to the increased oxidant load. In con-
clusion, stable tmTNF-  expression leads to persistent 
activation in endothelial cells, which resembles a dys-
functional and proinﬂ ammatory phenotype.  
 Enhanced Sprout Formation (Angiogenesis) in 
tmTNF-  Endothelial Cells 
 Microvascular endothelial cells are believed to initiate 
sprouting angiogenesis, which is observed to be increased 
in chronic inﬂ ammatory diseases. In order to test the hy-
pothesis that endothelial activation induces angiogenic 
activity, we assessed tmTNF-  -expressing endothelial 
cells in an in vitro assay for angiogenesis. Endothelial cells 
grown on microcarrier beads were embedded into a ﬁ brin 
gel in the presence or absence of VEGF to induce sprout-
ing. Randomly 50 individual beads with sprouts longer 
than the average size of beads were counted in the pres-
ence (2.5 ng/ml) or absence of VEGF 165 . tmTNF-  endo-
 Endothelial Activation Directly Links 
Angiogenesis and Inﬂ ammation 
 J Vasc Res 2006;43:193–204 197
0
10
20
30
40
50
60
C
o
u
n
ts
tmTNF-α
100 101 102 103 104
FL1-height
0
10
20
30
40
50
60
C
o
u
n
ts
100 101 102 103 104
FL2-height
100 101 102 103 104
FL1-height
0
C
o
u
n
ts
Control
10
20
30
40
50
60
100 101 102 103 104
FL2-height
0
C
o
u
n
ts
10
20
30
40
50
60
VCAM-1 ICAM-1
 Fig. 1. Increased expression of ICAM-1 and VCAM-1 in tmTNF-
  -expressing versus control endothelial cells. FACS analyses are 
shown of control and tmTNF-  -expressing endothelial cells stained 
either with anti-ICAM-1 or VCAM-1 antibodies as described in 
‘Materials and Methods’. As a positive control, samples from cells 
treated with soluble TNF-  (1 n M ) for 12 h are displayed in dark, 
while untreated samples are shown in light colors. Of note, in 
tmTNF-  -expressing cells, soluble TNF did not lead to signiﬁ cant 
further increase in ICAM-1 or VCAM-1 expression. Data shown 
are representative of experiments performed in duplicate and re-
peated at least four times with similar results. 
 Fig. 2. Increased ROS in tmTNF-  -expressing endothelial cells. 
Conﬂ uent control or tmTNF-  endothelial cells were tested for 
ROS production.  a Inhibition of DCFH oxidation, a marker of 
generalized oxidant production, in tmTNF cells by Trolox and by 
a combination of Trolox and 1 m M  L -NAME. Of note, while inhi-
bition of ROS-mediated DCFH oxidation was prominent at lower 
levels, at higher levels, inhibition was less prominent, suggesting a 
pro-oxidant activity at the higher concentrations.  a  p  ! 0.05: sig-
niﬁ cant difference from no inhibitor;  b  p  ! 0.05: signiﬁ cant differ-
ence from Trolox alone at same dose.  b ROS production, measured 
by DCFH oxidation, is increased in tmTNF-  cells compared with 
controls, and oxidant stress was signiﬁ cantly inhibited in both with 
Trolox (0.2 m M ).  a  p  ! 0.05: signiﬁ cant difference versus control 
cells;  b  p  ! 0.05: signiﬁ cant difference versus same cell treatment 
with/without inhibitor.  c Fluorescence of oxidized ethidium, a 
more speciﬁ c measure of superoxide production, demonstrates sig-
niﬁ cantly increased superoxide radicals in tmTNF cells versus con-
trol cells ( a  p  ! 0.05). Inhibition of NADPH oxidase by apocynin 
(Apo) (0.1 m M ) resulted in a signiﬁ cant attenuation ( b  p  ! 0.05), 
indicating that NADPH oxidase is a major contributor to the gain 
in superoxide levels over control. Similar inhibition was found with 
0.5 and 2 m M apocynin (data not shown). All experiments were 
performed in replicates (4–8), and experiments were repeated at 
least two additional times. RFU = Relative ﬂ uorescence unit. 
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 Fig. 3. Enhanced sprout formation (angio-
genesis) in tmTNF-  endothelial cells. A 
representative phase contrast micrograph 
of endothelial cell-coated cytodex beads 
depicting the sprouts of control cells in the 
absence ( a ) or presence ( b ) of VEGF and 
tmTNF-  -expressing cells in the absence 
( c ) or presence ( d ) of VEGF.  e Angiogenic 
sprouting activity in control ( ) ) and 
tmTNF ( $ ) endothelial cells embedded in 
ﬁ brin gels was quantiﬁ ed. tmTNF endo-
thelial cells demonstrated a signiﬁ cant 
( a  p  ! 0.01) increase in capillary-like sprouts 
(mean  8 SD) as compared with control 
cells, indicating an independence from 
growth factors. An additive increase in 
sprouting activity was observed with VEGF 
addition in the tmTNF-  cells ( b  p  ! 0.05). 
The data presented are from a representa-
tive experiment repeated four times inde-
pendently with similar results. 
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thelial cells demonstrated a signiﬁ cant (p  ! 0.05) increase 
in capillary-like sprouts as compared with control clones 
( ﬁ g. 3 ). This effect was comparable with the effects of 
VEGF alone on control cells, indicating that these cells 
become independent from requirement for exogenous 
growth factor-induced angiogenesis, although growth fac-
tor addition caused a further, additive increase in angio-
genesis in vitro ( ﬁ g. 3 ). 
 The Angiogenic Effect of Stable tmTNF-  Expression 
Is Direct 
 To further explore whether this angiogenic effect of 
stable tmTNF expression is due to the release of growth 
factors or to a direct effect on endothelial signaling, we 
have performed experiments quantifying the effect of 
conditioned media (CM) on endothelial sprouting ( ﬁ g. 4 ). 
Both control and tmTNF cells were seeded in T75 ﬂ asks 
 Fig. 4. Angiogenic effect of stable tmTNF-  
expression is direct. Control endothelial 
cells or stable tmTNF-  -transfected cells 
were seeded on cytodex-3 beads and em-
bedded into a 3-dimensional ﬁ brin gel to 
determine sprouting.  a CM collected from 
tmTNF-  endothelial cells were added to 
control cells. No signiﬁ cant change in 
sprout numbers was observed.  b Converse-
ly, CM from control cells was added to sta-
ble tmTNF-  -transfected cells. Again, no 
signiﬁ cant changes in sprout numbers were 
observed.  c Neutralizing antibodies to 
TNF, TNFRI, or isotype-matched IgGs 
were added to the media during the dura-
tion of the sprout formation assay. Note a 
signiﬁ cant decrease in sprout numbers 
(mean  8 SD) with anti-TNF as well as anti-
TNFRI ( a  p  ! 0.05) but not isotype-matched 
control ( b  p  1 0.05). The data presented are 
from a representative experiment repeated 
four times independently with similar re-
sults. 
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at 5,000 cells/cm 2  (about 10% conﬂ uency) and cultured 
to conﬂ uency for up to 4 days. The supernatant was col-
lected, centrifuged, and labeled as CM. Sprout formation 
was assessed with the addition of increasing concentra-
tions of CM from control cells to stable tmTNF  -trans-
fected cells and vice versa. As shown in  ﬁ gure 4 a, control 
cells treated with CM from tmTNF-  cells showed no 
increase in sprout formation, indicating that there were 
no stimulatory growth factors released by tmTNF-  en-
dothelial cells. Conversely, as shown in  ﬁ gure 4 b, no 
signiﬁ cant changes in sprout formation occurred in 
tmTNF-  cells treated with CM from control cells, ex-
cluding the secretion of inhibitory factor from control 
cells. Thus, the overall increased sprout formation seen 
in tmTNF-  cells as compared with control cells is indeed 
due to an autonomous signal effect of tmTNF-  rather 
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 Fig. 5. Increased angiogenesis in vivo in endothelial TNF-  -expressing Tie2-tmTNF mice. Matrigel solutions, 
supplemented with VEGF and FGF, were injected subcutaneously under the skin of 8-week-old animals. Matrigel 
plugs were excised after 2 weeks from 8 Tie2-tmTNF transgenic and 6 wild-type animals and embedded into par-
afﬁ n.  a ,  b Sections, stained with anti-CD34 antibodies, from wild-type (wt) and transgenic (Tie2-tmTNF) animals. 
Whereas in control animals only very few CD34-positive cells in vessel-like structures were found ( a ; arrows), in 
sections from Tie2-tmTNF mice, many vessel-like structures, positive for CD34, were observed ( b ). One vessel 
shows CD34-positive stain in the inner lining of a vascular-like structure (double arrow), whereas cells surround-
ing this structure only show blue H&E stain. Another microvessel-like CD34-positive structure reveals a sprout-
like appearance (single arrow).  c ,  d Quantiﬁ cation of cells/high-power ﬁ elds in sections stained with antibodies 
against the endothelial selective markers CD31 ( c ) and CD34 ( d ) in Tie2-tmTNF and wild-type mice. 
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than to an indirect autocrine-like effect by secretion of 
growth factors. Furthermore, neutralizing antibodies to 
either TNF-  (5   g/ml) or TNFRI (10   g/ml), but not 
isotype-matched IgG, signiﬁ cantly reduced sprout forma-
tion in tmTNF-  cells, further supporting the direct an-
giogenic role for tmTNF-  ( ﬁ g. 4 c). 
 Increased Vessel Growth in Tie2-tmTNF Mice 
 Next, we wanted to test in vivo whether endothelial 
cell activation mediated by stable transfection with 
TNF-  causes increased angiogenesis. In this assay, 
Matrigel solutions, incorporating growth factors (VEGF 
and FGF-2), were injected under the skin of Tie2-tmTNF 
transgenic and wild-type animals. After 2 weeks, neo-
vascularization was quantiﬁ ed in sections by immuno-
staining with CD31 and CD34, established markers for 
increased angiogenesis  [37–40] . As shown in  ﬁ gure 5 a 
and b, several cellular inﬁ ltrates, CD34-positive struc-
tures, resembling blood vessels (arrows) can be seen in 
plugs from transgenic mice, whereas only few such 
structures are visible in wild-type animals. Quantiﬁ ca-
tion of invading endothelial cells by use of the two 
markers CD31 and CD34 indicated signiﬁ cantly higher 
neovascularization in Tie2-tmTNF transgenic versus 
wild-type mice ( ﬁ g. 5 c, d). 
 Discussion 
 The present study demonstrates that continuous endo-
thelial activation can lead to angiogenesis in vivo  (Matri-
gel plug assay) and, in the complete absence of leukocytes, 
in vitro  (sprout assay). Although recruitment of leuko-
cytes is known to be a critical feature in pathologic in-
stances of angiogenesis, which in turn is dependent on 
expression of endothelial adhesion molecules and/or on 
chemokines, here, we show that angiogenesis can occur 
directly with endothelial cell activation, apart from the 
complementary angiogenic effects of leukocytes. Impor-
tantly, this direct angiogenic effect of continuous endo-
thelial cell activation also occurs in the absence of added 
growth factors in vitro.  
 Based on our and other studies, showing tmTNF-  to 
be upregulated in the highly angiogenic MethA ﬁ brosar-
coma of mice  [18] as well as in neovessels of atheroscle-
rotic plaques  [41] , we hypothesized that tmTNF-  con-
tributes to pathological angiogenesis. In this study, using 
the in vivo Matrigel model of angiogenesis, increased 
cellular inﬁ ltrates positive for the endothelial markers 
CD31 and CD34 could be observed in plugs from trans-
genic mice versus wild-type animals, suggesting that 
TNF-  -elicited endothelial cell activation may contrib-
ute to angiogenesis in vivo. Although it is generally as-
sumed that the endothelial marker CD31 is endothelial 
speciﬁ c  [37] , it can also be found on tumor-inﬁ ltrating 
macrophages and lead to an overestimation of angiogen-
esis  [42] . Therefore, we conﬁ rmed our results using an-
other marker, CD34, which is established in angiogenic 
vessels and absent on monocytes/macrophages  [39] . Our 
ﬁ nding that there are more CD34-positive than CD31-
positive cells in the Matrigel plug assay of transgenic 
animals may be explained by higher numbers of CD34, 
Flk-1- and AC133-positive endothelial progenitor cells, 
which may not be fully differentiated into endothelial 
cells as reported previously  [43] . In addition, this ﬁ nd-
ing of more CD34 versus CD31 cells is unlikely to be 
explained by CD34-positive leukocytic precursor cells 
as we did not observe leukocyte inﬁ ltration. Further-
more, both leukocytes and platelets can express CD31, 
so inﬁ ltration does not account for the higher number 
of CD34-positive cells. This is important in light of the 
assumption that proinﬂ ammatory cells including mac-
rophages modulate angiogenesis as growth factor-releas-
ing cells  [44] . However, this is not likely to be the cause 
of the stimulated angiogenesis in our assays since we 
have incorporated high concentrations of VEGF and 
bFGF into the Matrigel. 
 In further support of the hypothesis that the angio-
genic activity observed within the Matrigel plug assay is 
mediated by a direct effect of tmTNF-  -expressing endo-
thelial cells and not by leukocytes, we tested tmTNF-  -
expressing endothelial cells in an in vitro assay for angio-
genesis. It has previously been shown that this assay is 
suitable to study a variety of growth factors in vitro  [45, 
46] , and we demonstrated coherence of this assay with in 
vivo angiogenesis  [32, 38] . When control endothelial cells 
were stimulated with VEGF, increased sprout formation 
was observed, similar to that which we previously dem-
onstrated with other microvascular endothelial cells  [32] . 
In this study, tmTNF-  -expressing endothelial cells 
showed signiﬁ cantly more sprout formation than control 
cells. This effect was comparable with the increase ob-
served with an optimal concentration of VEGF. Interest-
ingly, sprout formation in tmTNF-  -expressing endo-
thelial cells in the presence of VEGF was further in-
creased. The observed increase in angiogenic activity of 
tmTNF-  -transfected endothelial cells could possibly be 
explained by a difference in signaling pathways, which 
renders tmTNF-  -activated endothelial cells proangio-
genic and independent from a requirement for stimula-
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tion with angiogenic growth factors. Furthermore, by 
adding CM from tmTNF cells onto control cells and vice 
versa from control cells onto tmTNF-  -expressing cells, 
we demonstrated that neither secretion of angiogenic fac-
tors from tmTNF-  -expressing cells nor release of inhib-
itory factors from control cells could explain the observed 
angiogenic difference between stable tmTNF-  -express-
ing and control cells. In conclusion, together with the neu-
tralizing anti-TNF-  antibody data ( ﬁ g. 4 c), we have 
provided evidence for the hypothesis that tmTNF-  acts 
as a direct stimulator of blood vessel growth in the 
sprout formation model of angiogenesis. Although the 
intracellular signaling pathways are not clear yet, these 
experiments open the possibility of a deﬁ nitive role for 
tmTNF-  as a connecting link between inﬂ ammation 
and angiogenesis.  
 Previously, we have shown that in vitro tmTNF-  
expression in human umbilical cord vein endothelial 
cells also caused an autonomous and continuous activa-
tion, exempliﬁ ed by persistent p38 mitogen-activated 
protein kinase and nuclear factor-  B activation and by 
tissue factor and interleukin 6 production  [18] . We also 
reported that Tie2-tmTNF (endothelial) expression in 
transgenic mice resulted in sustained expression of en-
dothelial adhesion molecules for leukocytes in vivo  [27] . 
In the present study, we demonstrate a stable and con-
tinuous surface expression of ICAM-1 and VCAM-1 on 
the surface of tmTNF-  -expressing murine endothelial 
cells, conﬁ rming the earlier in vivo study on adhesion 
molecules  [27] . Our results are in contrast to Canault et 
al.  [47] who reported no signiﬁ cant increase in ICAM-1 
in mouse aortic endothelial cells. There are several pos-
sibilities which may explain the observed differences. 
Microvascular endothelial cells used in this study com-
pared with macrovascular endothelial cells used by 
Canault et al.  [47] could contribute to the differences, 
as could the difference in the transgenic models being 
used. Additionally, in our studies of in vitro and in vivo 
models, endogenous production of soluble TNF-  is 
possible, whereas Canault et al.  [47] express the uncleav-
able tmTNF-  mutant in the absence of any soluble 
TNF-  using TNF-  gene-deﬁ cient animals as ‘genetic 
background’.  
 The elucidation of molecules and mechanisms under-
lying the continuous activated endothelium could pro-
vide new targets for drug development that spare the 
important infection-ﬁ ghting activities of leukocytes and 
the physiologic beneﬁ cial role of local TNF-  produc-
tion, but terminate untoward continuous endothelial ac-
tivation and its resultant contribution to pathologic in-
ﬂ ammation and angiogenesis. For instance, the ability of 
TNF-  to induce VCAM-1 and ICAM-1 may not only 
enhance emigration of leukocytes but also angiogenesis 
by yet another pathway. This requires proteolytic con-
version of these cellular adhesion molecules to their sol-
uble forms, which have been shown to synergize with 
TNF-  in both in vitro and in vivo models of angiogen-
esis  [48, 49] . The supposition that selective signal trans-
duction pathways, leading to expression of distinct vas-
cular adhesion molecules, are involved in processes of 
chronic inﬂ ammation is of clinical relevance, because it 
could lead to the development of more speciﬁ c blockers 
of pathways in the chronic activation, which differ from 
the acute activation sequence. Such remedies could be 
designed based on the ability to interfere with speciﬁ c 
signal transduction pathways, leading to selective adhe-
sion molecule expression.  
 Recently, ROS were identiﬁ ed as downstream media-
tors of angiogenic signaling by VEGF receptor 2/kinase 
insert domain receptor  [50] . In this study, we found that 
oxidant production was signiﬁ cantly increased in the 
tmTNF-  cells, indicating that with continuous activa-
tion there was also continuous oxidant production. The 
speciﬁ c sources and mechanisms are yet to be thoroughly 
determined, but our data using apocynin, a NADPH ox-
idase inhibitor, suggest that increased superoxide genera-
tion with chronic activation by tmTNF is largely due to 
NADPH oxidase based on the 70–75% suppression of the 
increased superoxide generation by apocynin. However, 
this speciﬁ c inhibition was not 100%, and thus, we have 
not absolutely ruled out smaller contributions from sec-
ondary NO synthase uncoupling due to superoxide/per-
oxynitrite-mediated tetrahydrobiopterin oxidation, cy-
clooxigenase activation, or mitochondrial changes. 
Nevertheless, the conclusion that NADPH oxidase is 
the primary source of increased oxidant production in 
tmTNF-expressing endothelial cells is consistent with 
acute activation of NADPH oxidase by exogenous, solu-
ble TNF  [34, 51, 52] , which is thought to be mediated by 
Rac1-associated assembly/activation of NADPH oxidase 
components  [51, 52] . Moreover, our data are consistent 
with reports that increased oxidants can actually drive 
further upregulation of expression of NADPH oxidase 
components [unpubl. data; see also ref.  34] . Of note, the 
steady increase in cellular oxidants affects signaling, par-
ticularly in the different arms of the mitogen-activated 
protein kinase pathways, in such a way to potentially ex-
plain the chronic upregulation of the leukocyte adhesion 
molecules and the direct angiogenic effects that we ob-
served  [53–55] . 
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 In conclusion, the present study speciﬁ cally addresses 
the link between the inﬂ ammation and blood vessel 
growth through the activated endothelium. Our hypoth-
esis that the proinﬂ ammatory activated endothelium pro-
motes angiogenesis in a manner that is both leukocyte 
dependent and leukocyte independent, and also in a 
growth factor-independent manner in vitro, is not only 
novel but also of biomedical signiﬁ cance given the in-
creasing number of reports on involvement of angiogen-
esis in diseases. Although much work remains to be ac-
complished, the putative link for continuous activated 
endothelium presented in this study could provide the 
impetus as an additional target for regulation of angio-
genesis in pathological diseases. 
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